Ascentage Pharma Group International (NASDAQ:AAPG) Shares Down 6% – Here’s Why

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) dropped 6% on Monday . The company traded as low as $17.19 and last traded at $17.1850. 2,433 shares were traded during trading, a decline of 64% from the average session volume of 6,834 shares. The stock had previously closed at $18.28.

Analysts Set New Price Targets

Several brokerages recently issued reports on AAPG. BTIG Research restated a “buy” rating and issued a $48.00 price objective on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Finally, B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $46.43.

Ascentage Pharma Group International Stock Down 5.1%

The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The firm has a 50-day moving average price of $18.22 and a 200 day moving average price of $20.85.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million during the quarter. Equities research analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current fiscal year.

Institutional Trading of Ascentage Pharma Group International

Hedge funds have recently made changes to their positions in the business. UBS Group AG grew its holdings in shares of Ascentage Pharma Group International by 149.4% in the third quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International during the 2nd quarter worth approximately $391,000. Finally, Citadel Advisors LLC acquired a new stake in Ascentage Pharma Group International during the 3rd quarter worth approximately $383,000.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.